

Division of Signal Transduction Therapy

Standard Operating Procedure

Preparation of active PKA [2 - 351]

Enzyme description:- PKA [2 - 351]

Clone number:- DU 951

Source:- Recombinant

Expression system:- *E.coli*

Tag:- N-terminal GST

Purification method:- GSH Sepharose

Expression level:- 1 mg/L

Calculated molecular mass:- 67, 239 Daltons

Purity:- >70 %

Activation protocol:- Constitutively active

Enzyme storage buffer:-

50 mM Tris-HCl pH 7.5, 50 % glycerol, 150 mM NaCl, 0.1 mM EGTA, 0.1 % 2-mercaptoethanol, 0.02 % Brij-35, 0.2 mM PMSF, 1 mM Benzamidine.

Storage temperature:- -20 °C

Assay:- Standard filter binding assay

Assay buffer:-

50 mM Tris-HCl pH 7.5, 0.1% 2-mercaptoethanol, 0.1 mM EGTA, 10 mM MgAc

Substrate:-

KEMPTide (LRRASLG) Final concentration: 30 µM

Specific activity range:- 250 – 500 U/mg

Division of Signal Transduction Therapy

Clone Data Sheet

PKA [2 - 351]

<u>Protein</u>	PKA [2 - 351]
<u>Clone number</u>	DU 951
<u>Species</u>	Human
<u>Accession number</u>	NM_002730
<u>Tags</u>	N-terminal GST
<u>Bacterially expressed protein</u>	MSPILGYWKIKGLVQPTRLLEYLEEKYEEHLYERDEGDKWRNKKFEL GLEFPNLPLYIDGDVKLTQSMAIIRYIADKHNLGGCPKERAESMLE GAVLDIYGVSRIAYSKDFETLKVDFSLKPEMLKMFEDRLCHKYLN GDHVTHPDFMLYDALDVVLYMDPMCLDAFPKLVCFKKRIEAIPQIDKY LKSSKYIAWPLQGWQATFGGGDHPPKS <u>DEVLFQGP</u> <u>LGS</u> GNAAAAKKG SEQESVKEFLAKAKEDFLKKWESPAQNTAHL DQFERIKTLGTGSFGRV MLVKHKETGNHYAMKILDQKVVKLKQIEHTLNEKRILQAVNFPFLVK LEFSFKDNSNL ^Y VM ^Y MEYVPGGEMFSHLRRIGRFSEPHARFYAAQIVLT FEYLHSLDLIYRDLKPENLLIDQQGYIQVTDFGFAKRVKGRTWTLCGT PEYLAPEIILSKGYNKAVDWWALGVLIYEMAAGYPPFFADQPIQIYEK IVSGKVRFPSHFSSDLKDLLRNLLQVDLTKRGFGNLKNGVNDIKNHKWF ATTDWIAIYQRKVEAPFIPFKGPGDTSNFDDYEEEIRVSINEKCGK EFSEF
<u>Native sequence</u>	Amino acids G2 – F351 (end) of human PKA. Residue G232 of the fusion protein is residue G2 of the native enzyme. The GST tag is located at residues 1 – 220.
<u>Protease cleavage</u>	PreScission (<u>LEVLFQGPGL</u>) at residues 221 – 229
<u>Cloning sites</u>	<i>Bam</i> H1 and <i>Sal</i> 1 site of pGEX6P-1

Division of Signal Tranduction Therapy

Nucleotide sequence of insert

GGATCCGGCAACGCCGCCGCCAAGAAGGGCAGCGAGCAGGAGAGC
GTGAAAGAATTCTTAGCAAAGCCAAGAAGATTTCTAAAAATGG
GAAAGTCCGCTCAGAACACAGCCCACCTGGATCAGTTGAACGAATC
AAGACCCTCGGCACGGCTCCTCGGGCGGGTATGCTGGTGAACAC
AAGGAGACCGGGAACCACTATGCCATGAAGATCCTCGACAAACAGAAG
GTGGTAAACTGAAACAGATCGAACACACCCCTGAATGAAAAGCGCATC
CTGCAAGCTGTCAACTTCCGTTCTCGTCAAACACTCGAGTTCTCCTTC
AAGGACAACCTCAAACCTATACATGGTCATGGAGTACGTGCCGGCGGG
GAGATGTTCTCACACCTACGGCGGATCGGAAGGTTCAGTGAGCCCCAT
GCCCGTTCTACGGGCCAGATCGCTGACCTTGAGTATCTGCAC
TCGCTGGATCTCATCTACAGGGACCTGAAGCCGGAGAATCTGCTCATT
GACCAGCAGGGCTACATTAGGTGACAGACTTCGGTTCGCCAAGCGC
GTGAAGGGCCGCACTTGGACCTTGTGCGGCACCCCTGAGTACCTGGCC
CCTGAGATTATCCTGAGCAAAGGCTACAACAAGGCCGTGGACTGGTGG
GCCCTGGGGTTCTTATCTATGAAATGCCGCTGGCTACCGCCCTTC
TTCGCAAGACCAGCCCACCATCCAGATCTATGAGAAGATCGTCTGGGAAG
GTGCGCTCCCTCCCACCTCAGCTGACTTGAAGGACCTGCTGCGG
AACCTCCTGCAGGTAGATCTCACCAAGCGCTTGGAACCTCAAGAAT
GGGGTCAACGATATCAAGAACCAAGTGGTTGCCACAACGTGACTGG
ATTGCCATCTACCAGAGGAAGGTGGAAGCTCCCTCATACCAAAGTTT
AAAGGCCCTGGGGATACGAGTAACTTGACGACTATGAGGAAGAAGAA
ATCCGGGTCTCCATCAATGAGAAGTGTGGCAAGGAGTTTCTGAGTTT
taggtcgac